Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Name:
36755084.pdf
Size:
2.435Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Calvisi, D. F.Boulter, L.
Vaquero, J.
Saborowski, A.
Fabris, L.
Rodrigues, P. M.
Coulouarn, C.
Castro, R. E.
Segatto, O.
Raggi, C.
van der Laan, L. J. W.
Carpino, G.
Goeppert, B.
Roessler, S.
Kendall, T. J.
Evert, M.
Gonzalez-Sanchez, E.
Valle, Juan W
Vogel, A.
Bridgewater, J.
Borad, M. J.
Gores, G. J.
Roberts, L. R.
Marin, J. J. G.
Andersen, J. B.
Alvaro, D.
Forner, A.
Banales, J. M.
Cardinale, V.
Macias, R. I. R.
Vicent, S.
Chen, X.
Braconi, C.
Verstegen, M. M. A.
Fouassier, L.
Affiliation
Institute of Pathology, University of Regensburg, Regensburg, GermanyIssue Date
2023
Metadata
Show full item recordAbstract
Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.Citation
Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, et al. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nat Rev Gastroenterol Hepatol. 2023 Feb 8. PubMed PMID: 36755084. Epub 2023/02/10. eng.Journal
Nature Reviews: Gastroenterology and HepatologyDOI
10.1038/s41575-022-00739-yPubMed ID
36755084Additional Links
https://dx.doi.org/10.1038/s41575-022-00739-yType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41575-022-00739-y
Scopus Count
Collections
Related articles
- Novel approaches in search for biomarkers of cholangiocarcinoma.
- Authors: Mocan LP, Ilieș M, Melincovici CS, Spârchez M, Crăciun R, Nenu I, Horhat A, Tefas C, Spârchez Z, Iuga CA, Mocan T, Mihu CM
- Issue date: 2022 Apr 21
- Future directions in the treatment of cholangiocarcinoma.
- Authors: Zhu AX
- Issue date: 2015 Apr
- The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
- Authors: Wang Y, Wan M, Zhou Q, Wang H, Wang Z, Zhong X, Zhang L, Tai S, Cui Y
- Issue date: 2015
- An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.
- Authors: Sahu R, Sharma P, Kumar A
- Issue date: 2023 Mar
- PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
- Authors: Loilome W, Yooyuen S, Namwat N, Sithithaworn P, Puapairoj A, Kano J, Noguchi M, Miwa M, Yongvanit P
- Issue date: 2012 Dec